Ractigen Therapeutics Reveals Innovative saRNA Therapy for Obesity Control at ADA 2026
Ractigen Therapeutics Unveils saRNA as a New Approach to Combat Obesity
Ractigen Therapeutics, a leader in biotechnology focused on small activating RNA (saRNA) therapeutics, has made waves in the scientific community with its latest innovations. At the upcoming American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, the company will showcase its groundbreaking research on LiCO-saUcp1. This preclinical data positions saRNA as a significant player in the fight against obesity.
Innovative Mechanism of Action
Ractigen's approach with LiCO-saUcp1 leverages a unique delivery platform, the Lipid-Conjugated Oligonucleotide (LiCO™). This therapy targets the Ucp1 gene, which is essential for stimulating metabolic thermogenesis—the body's process of converting fat into energy. Historically deemed
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.